Erasca, Inc. (ERAS)
13.61
-0.61
(-4.29%)
USD |
NASDAQ |
Nov 20, 16:00
13.74
+0.13
(+0.96%)
After-Hours: 20:00
Erasca Debt to Equity Ratio : 0.0473 for Sept. 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2026 | 0.0473 |
| June 30, 2026 | 0.1236 |
| March 31, 2026 | 0.1168 |
| December 31, 2025 | 0.145 |
| September 30, 2025 | 0.1388 |
| June 30, 2025 | 0.1328 |
| March 31, 2025 | 0.1272 |
| December 31, 2024 | 0.1225 |
| September 30, 2024 | 0.1176 |
| June 30, 2024 | 0.1196 |
| March 31, 2024 | 0.2144 |
| December 31, 2023 | 0.1764 |
| Date | Value |
|---|---|
| September 30, 2023 | 0.1674 |
| June 30, 2023 | 0.1589 |
| March 31, 2023 | 0.1502 |
| December 31, 2022 | 0.1338 |
| September 30, 2022 | 0.1491 |
| June 30, 2022 | 0.07 |
| March 31, 2022 | 0.0693 |
| December 31, 2021 | 0.0412 |
| September 30, 2021 | 0.0419 |
| June 30, 2021 | 0.0134 |
| March 31, 2021 | 0.0131 |
| December 31, 2020 | 0.0278 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Twist Bioscience Corp. | 0.107 |
| Revolution Medicines, Inc. | 0.5044 |
| Immunome, Inc. | 0.0251 |
| Tango Therapeutics, Inc. | 0.0318 |
| Oncolytics Biotech, Inc. | -0.0546 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 998.94M |
| Total Liabilities (Quarterly) | 82.20M |
| Shareholders Equity (Quarterly) | 916.74M |
| Current Ratio | 14.89 |
| Net Debt Paydown Yield | 0.02% |